FDA Lacks Timeliness In Reviewing Drug Ads: Report

Law360, New York (December 14, 2006, 12:00 AM EST) -- The U.S. Food and Drug Administration is taking too long to warn pharmaceutical companies about false and misleading advertisements, according to a congressional report.

The Government Accountability Office recommended in a report issued Thursday that the FDA document the criteria for prioritizing advertising materials for review, systematically apply that criteria and track which materials it reviews.

The Department of Health and Human Services, the parent agency of the FDA, disagreed with several of the recommendations contained in a draft of the report, saying that the changes...
To view the full article, register now.